For example, China’s inclusion of Osimertinib in reimbursement programs increased its use [33], while only 3.7% of EGFR-positive metastatic NSCLC patients in South Korea receive it as first-line therapy due to limited coverage [34]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.